Through clinical research, YQHXP combined with conventional drugs after 12 weeks of treatment was shown to reduce the levels of Lp-PLA2, hs-CRP, IL-6, NT-proBNP, ECV, and T1 in patients with heart failure, and the major cardiovascular adverse events of the two groups were not statistically significant, indicating that YQHXP can improve the clinical symptoms of patients with acute ST-segment elevation myocardial infarction after PCI and inhibit myocardial fibrosis. The gene discussed is PLA2G7; the disease is heart failure.